Sapphire Study
35 sites
(20 North America, 15 Europe)
Age > 21, Critically Ill
No AKI (Stage 2 or 3)
N = 744

Vienna Cohort
Age ≥ 18,
in ICU + Sepsis
N = 134

Duke Cohort
Age ≥ 18,
At least 1 risk factor
N = 123

Mayo Cohort
Age ≥ 18,
At least 1 risk factor
N = 265

Best Two Markers

Sapphire Study
35 sites
(20 North America, 15 Europe)
Age > 21, Critically Ill, no AKI (Stage 2 or 3)
N = 744

16 patients excluded
(2 withdrew consent, 7 lost to follow-up, 7 with invalid or missing test results)
N = 728

No AKI
N = 416

AKI Stage 1
N = 211

AKI Stage 2
N = 83

AKI Stage 3
N = 18

Within 12 hrs

Discovery

Validation